Corporate Finance
Cardiff Oncology faces potential $500M+ valuation hit as pivotal cancer trial data looms
ViaNews Editorial Team (Finance)•
#biotech risk
4 articles
Corporate Risk & Compliance
Zevra Therapeutics faces critical revenue risk tied to single rare disease drug
ViaNews Editorial Team (Finance)•
Biotech Investment Risk
Anebulo Pharmaceuticals Stakes Survival on Single Cannabis Toxicity Drug
ViaNews Editorial Team (Finance)•
Biotech Risk Assessment
Centessa Pharmaceuticals Faces High-Stakes Mechanistic Risk in Orexin Agonist Pipeline
ViaNews Editorial Team (Finance)•